Veterinary Immune Cell Therapy Development

Innovative cell therapies are progressing rapidly and stands to gain significantly from using unconventional yet clinically relevant animal models of disease. Veterinary immune cell therapies offer new avenues for treating diseases in companion animals. They also provide a valuable, underutilized resource that can facilitate the transition from laboratory and preclinical models to successful human clinical trials. BioVenic offers a comprehensive range of services for veterinary immune cell therapy development. These services include discovering disease targets for veterinary chimeric antigen receptor (CAR) therapy, CAR engineering and characterization, CAR packaging and transfection, as well as immune cell gene editing. Our tailored solutions are designed to tackle challenges in developing immune cell therapies for veterinary use, utilizing T-cells, B-cells, and Natural Killer (NK) cells.

Fig.1. Overall Scheme for CAR Therapy in Veterinary Medicine.^1,2

Veterinary CAR-T Therapy Development

CAR T-cell therapy is a widely-used and significant form of cellular immunotherapy that works by altering immune cells to target and destroy tumor cells, thereby amplifying the body's immune response. This cutting-edge treatment has shown success in clinical trials for blood, bone marrow, or lymph node tumors, such as leukemia and lymphoma. BioVenic is pioneering the application of CAR-T technology to treat diseases in companion animals, offering veterinary CAR-T therapy technologies to researchers.

Veterinary CAR-B Therapy Development

BioVenic is committed to partnering with researchers worldwide to develop CAR-modified animal immune cells and evaluate their ability to detect and destroy tumor cells. Our team leverages a specialized animal cell transformation platform to adaptively modify B cells and incorporate CAR, thereby enhancing their use in cancer treatment for companion animals. We provide a complete solution for veterinary CAR-B cell therapy development and evaluate its tumor-killing efficacy. Furthermore, we support the research advancement of combined cell therapy by integrating CAR-B cells with CAR-T cells to improve treatment outcomes.

Veterinary NK Cell Therapy Development

Natural killer (NK) cells play a vital role in the innate immune system of animals, with the unique capability to detect and destroy tumor and virus-infected cells independently of antibodies or major histocompatibility complex molecules. BioVenic specializes in offering tailored services for veterinary NK cell therapy development, aimed at accelerating the research phase of immune cell therapies. We provide researchers with innovative, secure, and practical designs for novel treatment strategies. Leveraging our cutting-edge technology platform and skilled research and development team, we deliver a full suite of services to support the development of veterinary NK cell therapies.

Veterinary Immune Cell Therapy Development Services

• Veterinary CAR Engineering

Drawing on our deep expertise in the structure and function of CARs, BioVenic has introduced a comprehensive range of technical services related to Veterinary CAR Engineering. By employing strategic design of the scFv domain, hinge domain, transmembrane domain, and intracellular domain, alongside cutting-edge gene editing technology and a high-throughput detection platform tailored for multiple animal targets, we support researchers in veterinary cell therapy in overcoming a wide array of research challenges.

• Veterinary CAR Phenotype Characterization

Prior to practical application, it is essential to perform in vitro characterization of CAR T-cells. This process generally involves co-incubating CAR T-cells with tumor cells and peripheral blood mononuclear cells (PBMCs), followed by conducting biochemical assays, microbiological assessments, and cytological analyses. Through these evaluations, scientists can determine the efficacy of CAR T-cells in targeting and eliminating tumor cells and assess safety-related factors such as cytotoxicity and cytokine production. Utilizing our flow cytometry, protein and metabolite detection platforms, and other high-throughput technologies, BioVenic provides extensive characterization services for preclinical veterinary CAR therapy studies, thereby supporting research and development in the field of veterinary CAR therapies.

• Veterinary CAR Therapy Disease Target Discovery

Species-specific differences result in unique interactions between CAR-T cells and tumor targets in various animal models. Therefore, developing CAR therapy disease targets tailored to specific animal species is crucial. BioVenic's Veterinary CAR Therapy Disease Target Discovery service caters to the needs of different animal types, organs, tissues, and disease categories by combining gene testing, mRNA expression analysis, and high-throughput detection of various proteins and metabolites. This all-encompassing platform aids researchers in identifying and evaluating animal disease targets, thereby advancing veterinary CAR-related cell therapies.

• Veterinary CAR Packaging and Transfection

A vital phase in the advancement of CAR T cell therapies is the integration of CAR constructs into T cells, enabling the precise identification and destruction of tumor cells. CAR-modified cell therapies offer significant promise for treating tumors in companion animals. Beyond disease target discovery, CAR development, and characterization, BioVenic's comprehensive service platform supports this crucial step of CAR gene transduction. Our offerings encompass the creation of viral or non-viral vectors, gene transfection into the target cell genome employing techniques like lentivirus or electroporation, and the stimulation of their expression.

• Veterinary CAR Immune Cell Gene Editing

BioVenic's gene editing team utilizes advanced technologies like CRISPR to genetically modify animal cells. This approach tackles challenges such as creating universal CAR cells, preventing immune cell self-destruction, boosting immune cell effectiveness, and averting cell exhaustion during treatments. Whether generating CAR cells through the CRISPR/Cas gene editing system or optimizing cells for veterinary therapy using base editing and gene knock-in/knock-out techniques, we are dedicated to offering global researchers comprehensive experimental design and implementation support, ensuring both feasibility and scientific integrity.

Why Choose Us?

BioVenic's research team maintains a consistent focus on the development of veterinary immune cell therapies and is committed to combining internal and external resources to provide technical support and diverse services for animal immune cell therapy development. Leveraging our expertise in CAR T cell, CAR B cell, and NK cell therapies, along with our robust gene editing, cell function analysis, lentiviral packaging, and protein and metabolite detection platforms, we are equipped to address a wide range of challenges that may arise during the development of veterinary immune cell therapies. If you are working on developing veterinary immune cell therapies, please feel free to contact us and let us know your research needs, and we will endeavor to provide you with the most suitable solutions.

References

1. Image retrieved from Figure 1 " Overall scheme for CAR therapy in veterinary medicine." Cockey and Cynthia, 2023, used under [CC BY 4.0] (https://creativecommons.org/licenses/by/4.0/). Without modification.
2. Cockey, James R., and Cynthia A. Leifer. "Racing CARs to veterinary immuno-oncology." Frontiers in Veterinary Science 10 (2023): 1130182.